Search Results - "Journal of thoracic oncology"

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 by Nicholson, Andrew G, Tsao, Ming S, Beasley, Mary Beth, Borczuk, Alain C, Brambilla, Elisabeth, Cooper, Wendy A, Dacic, Sanja, Jain, Deepali, Kerr, Keith M, Lantuejoul, Sylvie, Noguchi, Masayuki, Papotti, Mauro, Rekhtman, Natasha, Scagliotti, Giorgio, van Schil, Paul, Sholl, Lynette, Yatabe, Yasushi, Yoshida, Akihiko, Travis, William D

“…The 2021 WHO Classification of Thoracic Tumours was published earlier this year, with classification of lung tumors being one of the chapters. The principles…”
Get more information

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer by Tian, Sufang, Hu, Weidong, Niu, Li, Liu, Huan, Xu, Haibo, Xiao, Shu-Yuan

“…There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019…”
Get more information

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 by Paz-Ares, Luis, Vicente, David, Tafreshi, Ali, Robinson, Andrew, Soto Parra, Hector, Mazières, Julien, Hermes, Barbara, Cicin, Irfan, Medgyasszay, Balazs, Rodríguez-Cid, Jerónimo, Okamoto, Isamu, Lee, SungSook, Ramlau, Rodryg, Vladimirov, Vladimir, Cheng, Ying, Deng, Xuan, Zhang, Ying, Bas, Tuba, Piperdi, Bilal, Halmos, Balazs

“…In the randomized KEYNOTE-407 study (ClinicalTrials.gov, NCT02775435), pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel (chemotherapy)…”
Get more information

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial by Faivre-Finn, Corinne, Vicente, David, Kurata, Takayasu, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Spigel, David R, Garassino, Marina C, Reck, Martin, Senan, Suresh, Naidoo, Jarushka, Rimner, Andreas, Wu, Yi-Long, Gray, Jhanelle E, Özgüroğlu, Mustafa, Lee, Ki H, Cho, Byoung C, Kato, Terufumi, de Wit, Maike, Newton, Michael, Wang, Lu, Thiyagarajah, Piruntha, Antonia, Scott J

“…In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy,…”
Get more information

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial by Jotte, Robert, Cappuzzo, Federico, Vynnychenko, Ihor, Stroyakovskiy, Daniil, Rodríguez-Abreu, Delvys, Hussein, Maen, Soo, Ross, Conter, Henry J, Kozuki, Toshiyuki, Huang, Kuan-Chieh, Graupner, Vilma, Sun, Shawn W, Hoang, Tien, Jessop, Helen, McCleland, Mark, Ballinger, Marcus, Sandler, Alan, Socinski, Mark A

“…Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with…”
Get more information

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial by Nishio, Makoto, Barlesi, Fabrice, West, Howard, Ball, Simon, Bordoni, Rodolfo, Cobo, Manuel, Longeras, Pascale Dubray, Goldschmidt, Jr, Jerome, Novello, Silvia, Orlandi, Francisco, Sanborn, Rachel E, Szalai, Zsuzsanna, Ursol, Grigoriy, Mendus, Diana, Wang, Lijia, Wen, Xiaohui, McCleland, Mark, Hoang, Tien, Phan, See, Socinski, Mark A

“…We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with…”
Get more information

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee by Moreira, Andre L, Ocampo, Paolo S S, Xia, Yuhe, Zhong, Hua, Russell, Prudence A, Minami, Yuko, Cooper, Wendy A, Yoshida, Akihiko, Bubendorf, Lukas, Papotti, Mauro, Pelosi, Giuseppe, Lopez-Rios, Fernando, Kunitoki, Keiko, Ferrari-Light, Dana, Sholl, Lynette M, Beasley, Mary Beth, Borczuk, Alain, Botling, Johan, Brambilla, Elisabeth, Chen, Gang, Chou, Teh-Ying, Chung, Jin-Haeng, Dacic, Sanja, Jain, Deepali, Hirsch, Fred R, Hwang, David, Lantuejoul, Sylvie, Lin, Dongmei, Longshore, John W, Motoi, Noriko, Noguchi, Masayuki, Poleri, Claudia, Rekhtman, Natasha, Tsao, Ming-Sound, Thunnissen, Erik, Travis, William D, Yatabe, Yasushi, Roden, Anja C, Daigneault, Jillian B, Wistuba, Ignacio I, Kerr, Keith M, Pass, Harvey, Nicholson, Andrew G, Mino-Kenudson, Mari

“…A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a…”
Get more information

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial by Paz-Ares, Luis G, Ramalingam, Suresh S, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A, Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A, Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D, Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R, Reck, Martin

“…In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1)…”
Get more information

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11) by Yang, Yunpeng, Wang, Zhehai, Fang, Jian, Yu, Qitao, Han, Baohui, Cang, Shundong, Chen, Gongyan, Mei, Xiaodong, Yang, Zhixiong, Ma, Rui, Bi, Minghong, Ren, Xiubao, Zhou, Jianying, Li, Baolan, Song, Yong, Feng, Jifeng, Li, Juan, He, Zhiyong, Zhou, Rui, Li, Weimin, Lu, You, Wang, Yingyi, Wang, Lijun, Yang, Nong, Zhang, Yan, Yu, Zhuang, Zhao, Yanqiu, Xie, Conghua, Cheng, Ying, Zhou, Hui, Wang, Shuyan, Zhu, Donglei, Zhang, Wen, Zhang, Li

“…Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We…”
Get more information

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC by Gray, Jhanelle E, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F, Spigel, David R, Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A, Özgüroğlu, Mustafa, Antonia, Scott J

“…In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant…”
Get more information

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer by Goldstraw, Peter, Chansky, Kari, Crowley, John, Rami-Porta, Ramon, Asamura, Hisao, Eberhardt, Wilfried E E, Nicholson, Andrew G, Groome, Patti, Mitchell, Alan, Bolejack, Vanessa

“…The IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This…”
Get more information

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project by Hirsch, Fred R, McElhinny, Abigail, Stanforth, Dave, Ranger-Moore, James, Jansson, Malinka, Kulangara, Karina, Richardson, William, Towne, Penny, Hanks, Debra, Vennapusa, Bharathi, Mistry, Amita, Kalamegham, Rasika, Averbuch, Steve, Novotny, James, Rubin, Eric, Emancipator, Kenneth, McCaffery, Ian, Williams, J Andrew, Walker, Jill, Longshore, John, Tsao, Ming Sound, Kerr, Keith M

“…The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial-academic collaborative partnership to…”
Get more information

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC by Gao, Shugeng, Li, Ning, Gao, Shunyu, Xue, Qi, Ying, Jianming, Wang, Shuhang, Tao, Xiuli, Zhao, Jun, Mao, Yousheng, Wang, Bing, Shao, Kang, Lei, Wendong, Wang, Dali, Lv, Fang, Zhao, Liang, Zhang, Fan, Zhao, Ziran, Su, Kai, Tan, Fengwei, Gao, Yibo, Sun, Nan, Wu, Dawei, Yu, Yue, Ling, Yun, Wang, Zhijie, Duan, Chunjian, Tang, Wei, Zhang, Lei, He, Shun, Wu, Ning, Wang, Jie, He, Jie

“…Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant…”
Get more information

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification by Travis, William D, Brambilla, Elisabeth, Nicholson, Andrew G, Yatabe, Yasushi, Austin, John H M, Beasley, Mary Beth, Chirieac, Lucian R, Dacic, Sanja, Duhig, Edwina, Flieder, Douglas B, Geisinger, Kim, Hirsch, Fred R, Ishikawa, Yuichi, Kerr, Keith M, Noguchi, Masayuki, Pelosi, Giuseppe, Powell, Charles A, Tsao, Ming Sound, Wistuba, Ignacio

“…The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes…”
Get more information

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

“…In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced…”
Get more information

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies by Chung, Hyun Cheol, Piha-Paul, Sarina A, Lopez-Martin, Jose, Schellens, Jan H M, Kao, Steven, Miller, Jr, Wilson H, Delord, Jean-Pierre, Gao, Bo, Planchard, David, Gottfried, Maya, Zer, Alona, Jalal, Shadia I, Penel, Nicolas, Mehnert, Janice M, Matos, Ignacio, Bennouna, Jaafar, Kim, Dong-Wan, Xu, Lei, Krishnan, Suba, Norwood, Kevin, Ott, Patrick A

“…Pembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028…”
Get more information

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges by Seijo, Luis M, Peled, Nir, Ajona, Daniel, Boeri, Mattia, Field, John K, Sozzi, Gabriella, Pio, Ruben, Zulueta, Javier J, Spira, Avrum, Massion, Pierre P, Mazzone, Peter J, Montuenga, Luis M

“…The present review is an update of the research and development efforts regarding the use of molecular biomarkers in the lung cancer screening setting. The two…”
Get more information

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC by Lisberg, A, Cummings, A, Goldman, J W, Bornazyan, K, Reese, N, Wang, T, Coluzzi, P, Ledezma, B, Mendenhall, M, Hunt, J, Wolf, B, Jones, B, Madrigal, J, Horton, J, Spiegel, M, Carroll, J, Gukasyan, J, Williams, T, Sauer, L, Wells, C, Hardy, A, Linares, P, Lim, C, Ma, L, Adame, C, Garon, Edward B

“…Despite the significant antitumor activity of pembrolizumab in NSCLC, clinical benefit has been less frequently observed in patients whose tumors harbor EGFR…”
Get more information

Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial

“…The National Lung Screening Trial (NLST) randomized high-risk current and former smokers to three annual screens with either low-dose computed tomography…”
Get more information